GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Akebia Therapeutics Inc (STU:AX9) » Definitions » Operating Margin %

Akebia Therapeutics (STU:AX9) Operating Margin % : 23.57% (As of Mar. 2025)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Akebia Therapeutics's Operating Income for the three months ended in Mar. 2025 was €12.5 Mil. Akebia Therapeutics's Revenue for the three months ended in Mar. 2025 was €53.0 Mil. Therefore, Akebia Therapeutics's Operating Margin % for the quarter that ended in Mar. 2025 was 23.57%.

Good Sign:

Akebia Therapeutics Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Akebia Therapeutics's Operating Margin % or its related term are showing as below:

STU:AX9' s Operating Margin % Range Over the Past 10 Years
Min: -8889.9   Med: -85.46   Max: -11.91
Current: -11.91


STU:AX9's Operating Margin % is ranked worse than
78.83% of 973 companies
in the Drug Manufacturers industry
Industry Median: 6.89 vs STU:AX9: -11.91

Akebia Therapeutics's 5-Year Average Operating Margin % Growth Rate was 28.60% per year.

Akebia Therapeutics's Operating Income for the three months ended in Mar. 2025 was €12.5 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was €-20.5 Mil.


Akebia Therapeutics Operating Margin % Historical Data

The historical data trend for Akebia Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Operating Margin % Chart

Akebia Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -128.23 -124.97 -22.17 -23.67 -31.47

Akebia Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.63 -19.99 -33.41 -30.77 23.57

Competitive Comparison of Akebia Therapeutics's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Operating Margin % falls into.


;
;

Akebia Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Akebia Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-48.145 / 152.972
=-31.47 %

Akebia Therapeutics's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2025 ) / Revenue (Q: Mar. 2025 )
=12.5 / 53.036
=23.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Akebia Therapeutics  (STU:AX9) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Akebia Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics Business Description

Traded in Other Exchanges
Address
245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Akebia Therapeutics Headlines

No Headlines